Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics
Regeneron Pharmaceuticals, Inc. (REGN)
Today's Latest Price: $515.56 USD
Updated Jan 27 4:00pm
Add REGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
REGN Stock Summary
- REGN has a higher market value than 96.01% of US stocks; more precisely, its current market capitalization is $58,058,878,242.
- With a year-over-year growth in debt of 278.11%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 94.37% of about US stocks.
- In terms of volatility of its share price, REGN is more volatile than merely 12.89% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Regeneron Pharmaceuticals Inc are VRTX, SNPS, EA, ADI, and CDNS.
- REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to www.regeneron.com.
REGN Stock Price Chart Interactive Chart >
REGN Price/Volume Stats
| Current price | $515.56 | 52-week high | $664.64 |
| Prev. close | $544.10 | 52-week low | $328.13 |
| Day low | $512.94 | Volume | 1,432,882 |
| Day high | $541.97 | Avg. volume | 1,013,523 |
| 50-day MA | $506.71 | Dividend yield | N/A |
| 200-day MA | $569.03 | Market Cap | 55.01B |
Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $515.56 | $608.09 | 12% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Regeneron Pharmaceuticals Inc. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 54th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 12.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Regeneron Pharmaceuticals Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is 72.22 -- which is good for besting 94.36% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 15.58% of the free cash flow producing stocks we're observing.
- REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.27% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 10% |
| 1% | 11% |
| 2% | 12% |
| 3% | 13% |
| 4% | 14% |
| 5% | 15% |
FONR, CMD, DXCM, UNH, and FZMD can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...